The field of kidney cancer treatment could soon be expanding thanks to the inclusion of PARP inhibitors, vaccination-based strategies and emerging therapies such as Fotivda (tivozanib), according to research presented at the 2019 Kidney Cancer Research Summit.
Oral mucositis can be debilitating, but one expert explains the steps you can take to help mitigate this side effect of radiation and chemotherapy.
Why US cancer registries need to be modernized to help us better understand cancer.
Here are the top five CURE® stories for October 2019.
At the end of the day, I'm still a man who likes a plan. Even if it doesn't always work out as expected.
From a palliative care bill clearing the House to a Washington Redskins player revealing a cancer diagnosis, here’s what is making headlines in the cancer space this week.
The Food and Drug Administration’s recent approval of Zejula for certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer was the first PARP inhibitor approved for the treatment, not the maintenance, of these women.
During an evening co-hosted by Paula Abdul, the organization fulfilled wishes for four children with cancer and honored a breast cancer survivor and a volunteer.
A two-time cancer survivor shares ideas to cope with the lonely, frightening feelings that came with her breast cancer diagnosis.
Here’s a sneak peek at what’s inside our Fall 2019 issue.
During the 2019 Prostate Cancer Consensus Conference, one expert discussed three clinical trials and the future of genetic testing in patients with the disease.
Looking back on Day One in the chemotherapy journey.
Phase 3 clinical trial results showed that certain mouthwashes benefit and reduce pain in patients with oral mucositis.
Is there anything I would tell my younger self about any risks for cancer? What about now: what can I suggest to my sister? What do I need to tell my children about their risks for cancer?
Forty-eight percent of those surveyed by The Pink Fund said the cost of transportation was a barrier to receiving treatment and 60% missed an appointment or were late to one because of transportation issues.
Facing those drawn-out days between a breast cancer diagnosis and mastectomy surgery.
Here is a list of the recent trial initiations that occurred within the cancer space in October.
CURE® asked its readers for their thoughts on “Pinktober,” which ran the gamut of emotions.
Imagine Dragons founded the Tyler Robinson Foundation to help families afford the nonmedical costs of pediatric cancer.
A single question acknowledging someone else's experience can lift the heavy feeling of cancer isolation.
Using artificial intelligence to analyze huge stores of information known as big data boosts the effectiveness of cancer diagnosis and treatment.
A two-time cancer survivor learns more about pancreatic cysts and discusses the value and cautions of genetic testing.
Radiation and chemotherapy increase a patient’s risk of developing the side effect known as oral mucositis, but certain actions can be taken to improve quality of life.
From the Food and Drug Administration’s call to action over breast implant-associated illness and lymphoma to a four-time survivor’s college football debut, here’s what is making headlines in the cancer space this week.
Faith may influence a breast cancer recovery by helping a person gain a deeper understanding of their life’s meaning and purpose.
The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency-positive status.
Sometimes starting a new chapter in life can be good for cancer survivors.
Patients with recurrent, metastatic or persistent cervical cancer may benefit from the TIL immunotherapy LN-145.
We've got a sneak peek at what’s inside CURE®'s 2019 Genitourinary Cancers special issue.
Patients with recurrent or metastatic cervical cancer were treated with combination Opdivo and Yervoy in the CheckMate-358 clinical trial.
